COSTA, CLAUDIA
COSTA, CLAUDIA
The effectiveness of vismodegib in patients with advanced periocular basal cell carcinoma: a case series of 13 patients
2022 Villani, A; Costa, C; Cappello, M; Fabbrocini, G; Scalvenzi, M
BRIT‐1 expression and its relationship with PARP‐1 and CAF‐1/p60 in cutaneous melanoma
2021 Russo, Daniela; Travaglino, Antonio; Varricchio, Silvia; Merolla, Francesco; Ilardi, Gennaro; Raffone, Antonio; Scalvenzi, Massimiliano; Costa, Claudia; Fabbrocini, Gabriella; Staibano, Stefania; Mascolo, Massimo
Tissue Expression of Carbonic Anhydrase IX Correlates to More Aggressive Phenotype of Basal Cell Carcinoma
2021 Russo, Daniela; Varricchio, Silvia; Ilardi, Gennaro; Martino, Francesco; Di Crescenzo, Rosa Maria; Pignatiello, Sara; Scalvenzi, Massimiliano; Costa, Claudia; Mascolo, Massimo; Merolla, Francesco; Staibano, Stefania
Melanoma Screening Days During the Coronavirus Disease 2019 (COVID-19) Pandemic: Strategies to Adopt
2020 Villani, A.; Fabbrocini, G.; Costa, C.; Scalvenzi, M.
Drug holiday regimen for vismodegib treatment in patients with multiple primary basal cell carcinomas
2020 Villani, A.; Costa, C.; Fabbrocini, G.; Scalvenzi, M.
Trends in epidemiology of melanoma in situ in a center of South-Italy: Data from a melanoma reference center during the period 2004–2018
2020 Villani, A.; Costa, C.; Fabbrocini, G.; Cinelli, E.; Greco, V.; Scalvenzi, M.
Assessment of the adverse events related to hedgehog pathway inhibitor therapy for basal cell carcinoma: A single-centre retrospective study
2021 Villani, A.; Fabbrocini, G.; Costa, C.; Cappello, M.; Scalvenzi, M.
Hair Loss in Patients Treated with Vismodegib: A Single-Center Retrospective Study
2020 Villani, A.; Fabbrocini, G.; Costa, C.; Scalvenzi, M.
Dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor sonidegib to manage adverse effects: A retrospective case series
2021 Villani, Alessia; Costa, Claudia; Fabbrocini, Gabriella; Ruggiero, Angelo; Scalvenzi, Massimiliano
Awareness on sun protection behavior among melanoma and nonmelanoma skin cancer patients: An Italian tertiary cancer center experience
2021 Villani, A.; Fabbrocini, G.; Costa, C.; Scalvenzi, M.
Response to "Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT) trial at 42 months"
2021 Villani, Alessia; Fabbrocini, Gabriella; Costa, Claudia; Scalvenzi, Massimiliano
Merkel Cell Carcinoma: Therapeutic Update and Emerging Therapies
2019 Villani, Alessia; Fabbrocini, Gabriella; Costa, Claudia; Carmela Annunziata, Maria; Scalvenzi, Massimiliano
Dermoscopic patterns of intradermal naevi
2020 Greco, Vincenzo; Cappello, Milena; Megna, Matteo; Costa, Claudia; Villani, Alessia; Fabbrocini, Gabriella; Marino, Vincenzo; Scalvenzi, Massimiliano
A rare evolution of porokeratosis
2020 Mascolo, Massimo; Patrì, Angela; Pace, Mirella; Costa, Claudia; Varricchio, Silvia; Travaglino, Antonio; Scalvenzi, Massimiliano
Complete remission of an advanced basal cell carcinoma after only 3-month treatment with sonidegib: Report of a case and drug management during COVID-19 pandemic
2020 Villani, A.; Fabbrocini, G.; Costa, C.; Scalvenzi, M.
Comment on: “Second primary melanomas in a cohort of 977 melanoma patients within the first 5 years of monitoring”
2020 Villani, A.; Fabbrocini, G.; Greco, V.; Costa, C.; Scalvenzi, M.
Low-Dose Vismodegib as Maintenance Therapy After Locally Advanced Basal Cell Carcinoma Complete Remission: High Efficacy with Minimal Toxicity
2020 Scalvenzi, M.; Cappello, M.; Costa, C.; Fabbrocini, G.; Luciano, M.; Villani, A.
Patients with advanced basal cell carcinomas in treatment with sonic hedgehog inhibitors during the coronavirus disease 2019 (COVID-19) period: Management and adherence to treatment
2020 Villani, A.; Fabbrocini, G.; Costa, C.; Scalvenzi, M.
Sonidegib: Safety and Efficacy in Treatment of Advanced Basal Cell Carcinoma
2020 Villani, A.; Fabbrocini, G.; Costa, C.; Scalvenzi, M.
Second primary melanoma: incidence rate and risk factors
2020 Villani, A.; Fabbrocini, G.; Costa, C.; Greco, V.; Scalvenzi, M.
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| The effectiveness of vismodegib in patients with advanced periocular basal cell carcinoma: a case series of 13 patients | 1.1 Articolo in rivista | 2022 | Villani, A; Costa, C; Cappello, M; Fabbrocini, G; Scalvenzi, M | |
| BRIT‐1 expression and its relationship with PARP‐1 and CAF‐1/p60 in cutaneous melanoma | 1.1 Articolo in rivista | 2021 | Russo, Daniela; Travaglino, Antonio; Varricchio, Silvia; Merolla, Francesco; Ilardi, Gennaro; Raffone, Antonio; Scalvenzi, Massimiliano; Costa, Claudia; Fabbrocini, Gabriella; Staibano, Stefania; Mascolo, Massimo | |
| Tissue Expression of Carbonic Anhydrase IX Correlates to More Aggressive Phenotype of Basal Cell Carcinoma | 1.1 Articolo in rivista | 2021 | Russo, Daniela; Varricchio, Silvia; Ilardi, Gennaro; Martino, Francesco; Di Crescenzo, Rosa Maria; Pignatiello, Sara; Scalvenzi, Massimiliano; Costa, Claudia; Mascolo, Massimo; Merolla, Francesco; Staibano, Stefania | |
| Melanoma Screening Days During the Coronavirus Disease 2019 (COVID-19) Pandemic: Strategies to Adopt | 1.1 Articolo in rivista | 2020 | Villani, A.; Fabbrocini, G.; Costa, C.; Scalvenzi, M. | |
| Drug holiday regimen for vismodegib treatment in patients with multiple primary basal cell carcinomas | 1.1 Articolo in rivista | 2020 | Villani, A.; Costa, C.; Fabbrocini, G.; Scalvenzi, M. | |
| Trends in epidemiology of melanoma in situ in a center of South-Italy: Data from a melanoma reference center during the period 2004–2018 | 1.1 Articolo in rivista | 2020 | Villani, A.; Costa, C.; Fabbrocini, G.; Cinelli, E.; Greco, V.; Scalvenzi, M. | |
| Assessment of the adverse events related to hedgehog pathway inhibitor therapy for basal cell carcinoma: A single-centre retrospective study | 1.1 Articolo in rivista | 2021 | Villani, A.; Fabbrocini, G.; Costa, C.; Cappello, M.; Scalvenzi, M. | |
| Hair Loss in Patients Treated with Vismodegib: A Single-Center Retrospective Study | 1.1 Articolo in rivista | 2020 | Villani, A.; Fabbrocini, G.; Costa, C.; Scalvenzi, M. | |
| Dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor sonidegib to manage adverse effects: A retrospective case series | 1.1 Articolo in rivista | 2021 | Villani, Alessia; Costa, Claudia; Fabbrocini, Gabriella; Ruggiero, Angelo; Scalvenzi, Massimiliano | |
| Awareness on sun protection behavior among melanoma and nonmelanoma skin cancer patients: An Italian tertiary cancer center experience | 1.1 Articolo in rivista | 2021 | Villani, A.; Fabbrocini, G.; Costa, C.; Scalvenzi, M. | |
| Response to "Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT) trial at 42 months" | 1.1 Articolo in rivista | 2021 | Villani, Alessia; Fabbrocini, Gabriella; Costa, Claudia; Scalvenzi, Massimiliano | |
| Merkel Cell Carcinoma: Therapeutic Update and Emerging Therapies | 1.1 Articolo in rivista | 2019 | Villani, Alessia; Fabbrocini, Gabriella; Costa, Claudia; Carmela Annunziata, Maria; Scalvenzi, Massimiliano | |
| Dermoscopic patterns of intradermal naevi | 1.1 Articolo in rivista | 2020 | Greco, Vincenzo; Cappello, Milena; Megna, Matteo; Costa, Claudia; Villani, Alessia; Fabbrocini, Gabriella; Marino, Vincenzo; Scalvenzi, Massimiliano | |
| A rare evolution of porokeratosis | 1.1 Articolo in rivista | 2020 | Mascolo, Massimo; Patrì, Angela; Pace, Mirella; Costa, Claudia; Varricchio, Silvia; Travaglino, Antonio; Scalvenzi, Massimiliano | |
| Complete remission of an advanced basal cell carcinoma after only 3-month treatment with sonidegib: Report of a case and drug management during COVID-19 pandemic | 1.1 Articolo in rivista | 2020 | Villani, A.; Fabbrocini, G.; Costa, C.; Scalvenzi, M. | |
| Comment on: “Second primary melanomas in a cohort of 977 melanoma patients within the first 5 years of monitoring” | 1.1 Articolo in rivista | 2020 | Villani, A.; Fabbrocini, G.; Greco, V.; Costa, C.; Scalvenzi, M. | |
| Low-Dose Vismodegib as Maintenance Therapy After Locally Advanced Basal Cell Carcinoma Complete Remission: High Efficacy with Minimal Toxicity | 1.1 Articolo in rivista | 2020 | Scalvenzi, M.; Cappello, M.; Costa, C.; Fabbrocini, G.; Luciano, M.; Villani, A. | |
| Patients with advanced basal cell carcinomas in treatment with sonic hedgehog inhibitors during the coronavirus disease 2019 (COVID-19) period: Management and adherence to treatment | 1.1 Articolo in rivista | 2020 | Villani, A.; Fabbrocini, G.; Costa, C.; Scalvenzi, M. | |
| Sonidegib: Safety and Efficacy in Treatment of Advanced Basal Cell Carcinoma | 1.1 Articolo in rivista | 2020 | Villani, A.; Fabbrocini, G.; Costa, C.; Scalvenzi, M. | |
| Second primary melanoma: incidence rate and risk factors | 1.1 Articolo in rivista | 2020 | Villani, A.; Fabbrocini, G.; Costa, C.; Greco, V.; Scalvenzi, M. |